Novartis Ag (NVSEF) Net Cash Flow (2009 - 2025)

Novartis Ag has disclosed Net Cash Flow across 15 years of filings, most recently posting -$2.1 billion for Q4 2025.

• Net Cash Flow for Q4 2025 came in at -$2.1 billion, up 60.53% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.8 billion (up 48.46% YoY), and the FY2025 annual result was -$600.0 million, up 63.33% from the prior year.
• Net Cash Flow came in at -$2.1 billion for Q4 2025 at Novartis Ag, down from -$860.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $15.8 billion in Q4 2023 to a low of -$10.2 billion in Q2 2022.
• The 5-year median for Net Cash Flow is -$879.5 million (2024), against an average of -$1.1 billion.
• Across the five-year window, Net Cash Flow tumbled 886.32% in 2022 and jumped 281.63% in 2023, its largest moves.
• Novartis Ag's Net Cash Flow stood at -$4.3 billion in 2021, then plunged by 101.13% to -$8.7 billion in 2022, then surged by 281.63% to $15.8 billion in 2023, then slumped by 133.77% to -$5.3 billion in 2024, then jumped by 60.53% to -$2.1 billion in 2025.
• The last three Net Cash Flow figures came in at -$2.1 billion (Q4 2025), -$860.0 million (Q3 2025), and -$792.0 million (Q2 2025), per Business Quant data.